This tiny, wall-less bacterium is a master of disguise and persistent respiratory infection.
In short: Mycoplasma pneumoniae is one of the smallest self-replicating organisms, lacking a cell wall and relying on host resources to survive. Often called the Eaton agent, this pathogen uses a specialized organelle to attach to human cells, mimicking host membranes to evade the immune system and cause lingering respiratory distress.
Mycoplasma pneumoniae belongs to the class Mollicutes, a group of bacteria defined by their lack of a peptidoglycan cell wall. This structural absence renders them inherently resistant to common antibiotics like beta-lactams, which target cell wall synthesis. Instead, these organisms rely on a rigid cytoskeleton reinforced with cholesterol—which they must acquire from their host—to maintain osmotic stability. Their extremely small size, typically 0.1 to 0.2 micrometers in width, makes them invisible to standard light microscopy, requiring specialized techniques for identification.
The organism's path to discovery was complex. Initially isolated in 1944 by Monroe Eaton from human pneumonia cases, the agent was long suspected to be a virus due to its ability to pass through filters and grow in embryonated chicken eggs. It was not until 1961 that Robert Chanock and Leonard Hayflick identified it as a mycoplasma. This breakthrough established it as the first free-living microorganism proven to cause human disease, a discovery for which Hayflick later received the Presidential Award from the International Organization of Mycoplasmology.
Pathogenesis is driven by a specialized attachment organelle that facilitates both motility and adhesion to respiratory epithelial cells. Once attached, the bacterium releases cytotoxic factors, including the CARDS toxin and hydrogen sulfide, which disrupt tissue and cause cilia loss. Furthermore, the pathogen can fuse with host cells and persist intracellularly, effectively hiding from the immune system and resisting standard antibiotic treatments. This ability to mimic host cell surface composition not only aids in evasion but can also trigger autoimmune responses, contributing to chronic conditions like asthma and COPD.
Treatment typically involves macrolides, tetracyclines, or fluoroquinolones, which inhibit protein synthesis. However, rising resistance—particularly in Asia, where rates have reached as high as 100%—has become a significant clinical challenge. This resistance is largely driven by mutations in the 23S rRNA gene, which interfere with the binding of macrolide antibiotics. Because the organism is difficult to culture, clinicians often rely on treatment response and local resistance estimates rather than routine susceptibility testing.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Mycoplasma pneumoniae
- Also: my.clevelandclinic.org — What Is Mycoplasma pneumoniae?
To cite this card, link to https://intellectplus.co.uk/app/gardening-mycoplasma-pneumoniae.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Prokaryotes · More in Gardening · Latest · A–Z · All topics